Latest Medtech News
Anaconda Biomed, a Barcelona-based medical device company, has raised $56 million to advance its mechanical thrombectomy catheter portfolio and complete the pivotal investigational device exemption (IDE) study for its ANA funnel catheter. The round was led by Omega Funds, with new investor FOCO, a co-investment fund established by the Spanish government and managed by the Spanish Development Finance Company (COFIDES), also joining. Existing investors Asabys, Ysios Capital, and CDTI also participated.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.
A key portion of the funding will go toward completing the ATHENA pivotal IDE study (NCT06370182), which is evaluating the ANA funnel catheter. The device combines aspiration power with flow-arrest and flow-reversal mechanisms, designed to improve clot capture, reduce embolic complications, and maximize brain reperfusion during mechanical thrombectomy for acute ischemic stroke.
For Anaconda Biomed, the funding provides runway to complete the clinical and regulatory work needed ahead of a planned US market entry, where the company will face established competition, particularly Penumbra, now part of Boston Scientific following a $14.5 billion acquisition, and Imperative Care, which together hold close to 60% of the US neuro aspiration thrombectomy market. For the broader MedTech space, the round adds to continued investment in an underpenetrated category: of roughly 4.55 million annual global deaths from ischemic stroke, only about 30% of eligible patients currently receive mechanical thrombectomy, translating to an estimated 270,000 procedures performed globally in 2026 against a global neurovascular thrombectomy device market projected to roughly double by 2035, according to GlobalData.
CEO Trent Reutiman said the funding reflects "growing confidence in our technology platform" as the company works toward reducing disability and death from large vessel occlusive stroke.
